Cancer research funding in USA.
نویسنده
چکیده
Despite the current stability of overall cancer incidence in the USA, for the past 2 years cancer-related deaths have fallen. This gratifying trend, laid out in the American Cancer Society’s Annual Report to the Nation (Howe et al., 2006), has left cancer researchers with the rosy feeling that their hard work is starting to pay off on a grand scale. And, with such obvious evidence of the benefits of investment to show to federal decision-makers, cancer researchers rightly presumed that funding for their work would increase in line with the predicted increase in cancer burden – expected to overtake heart disease as the leading cause of death by 2010. Unfortunately, the high-level commitment to cancer research exemplified by Richard Nixon’s War on Cancer, launched in 1971, seems to have vanished over the past few years. Instead, the National Cancer Institute (NCI), the USA’s main cancer research funding body, has been struggling to cope with stagnating appropriations from Congress, which equate to actual funding cuts – and the future is not looking any better. Last year, the NCI received around US$4.8 billion dollars from federal funds, an increase of less than 0.5% over the previous year’s income and a continuation of the trend for below-inflation rises begun in 2003. With costs of doing research growing by at least 3% a year, these miniscule increases are putting real pressure on the NCI and its associated structures to cut back on large projects, eliminate smaller ones, and reduce the scale of their investment. According to Dr Richard Schilsky, President Elect of the American Society of Clinical Oncology, and a Professor of Medicine and Associate Dean at the University of Chicago Medical Center, these cuts could not have come at a worse time. ‘‘We have more drugs in pipeline than ever before and a better understanding of cancer. In many ways, this is intellectually the most exciting time in cancer research. But, paradoxically, it is a time when young people are questioning whether they can have a viable career,’’ he said.
منابع مشابه
Combined pan-RAF and MEK inhibition overcomes multiple resistance mechanisms to selective RAF inhibitors Authors
Affiliations Department of Medical Oncology and Center for Cancer Genome Discovery, DanaFarber Cancer Institute, Boston, MA, USA Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA The Broad Institute, Cambridge, MA, USA Division of Cancer Therapeutics, Institute of Cancer Research, London, SW7 3RP, United Kingdom Corresponding author Levi A. Garraway, ...
متن کاملFuture cancer research priorities in the USA: a Lancet Oncology Commission.
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, pro...
متن کاملFDG PET in the management of lung cancer
We describe a patient with newly diagnosed limy cancer. Staging was performed with CT and mediastinoscopy. FDG PET scan was performed and confirmed increased metabolic activity in the primary tumor as well as the hilar lymph node. Seven months after initial presentation, the patient was found to have two lytic lesions in the pelvis on plain radiograph. Hone scan was negative but PET demon...
متن کاملMeeting standards.
Nigel Williams' article "Tobacco funding debate smolders" (News & Comment, 4 Oct., p. 28) highlights the disturbing tendency of some philanthropic organizations to politicize science in a way that threatens independent research. The Cancer Research Campaign (CRC) in Britain threatened to halt future funding for Cambridge University scientists because the university accepted a donation from Brit...
متن کاملOccasional report International gastroenterology research: subject areas, impact, and funding
Aims—To examine the volume and potential impact of gastroenterology research outputs from 1985 to 1998 from 14 developed countries; the overlap with research in cancer, infectious diseases, and genetics; and the funding sources for this research. To determine if countries’ research outputs correlated with their burden of corresponding diseases and inputs to their research. Methods—Selective ret...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Molecular oncology
دوره 1 2 شماره
صفحات -
تاریخ انتشار 2007